-
Multiple myeloma is a form of blood cancer that targets the plasma cells (a type of white blood cell) within the bone marrow. or is a commonly used proteasome inhibitor for the treatment of myeloma. Proteasomes are protein molecules present in all cells that contribute significantly to cellular function...
-
Developed by Janssen Biotech and Genmab, Darzalex™ or daratumumab became the first FDA-approved monoclonal antibody for the treatment of patients with multiple myeloma. Darzalex Uses Approved for the treatment of individuals with multiple myeloma, Darzalex is available as injections, taken intravenously at a 16-mg per kg. Daratumumab may sometimes...
-
Multiple myeloma is a type of cancer that manifests in a white blood cell known as a plasma cell. Plasma cells play an important role in warding off infections by producing antibodies that identify and strike pathogens. In its early stages, multiple myeloma may not present itself with...
-
or is an immunotherapy drug that is a more powerful version of drugs such as and . Produced by Celgene, has been approved to be used for the treatment of individuals with myeloma who have previously been on a proteasome inhibitor treatment and also those whose myeloma began advancing...
-
Chemotherapy is a common treatment method for multiple myeloma that works by introducing cancer-destroying agents into the body. As these chemotherapy drugs enter the bloodstream and circulate throughout the body, they are highly effective in killing myeloma cells. Chemotherapy drugs can either be taken orally or intravenously. If...
-
If you don’t experience any multiple myeloma symptoms, your oncologist may prefer to monitor your condition closely instead of starting you on a treatment immediately. If you experience symptoms, however, your oncologist will create a treatment protocol based on your particular circumstances. The goal of most multiple myeloma treatments...
Multiple myeloma is a form of blood cancer that targets the plasma cells (a type of white blood cell) within the bone marrow. or is a commonly used proteasome inhibitor for the treatment of myeloma. Proteasomes are protein molecules present in all cells that contribute significantly to cellular function...
Developed by Janssen Biotech and Genmab, Darzalex™ or daratumumab became the first FDA-approved monoclonal antibody for the treatment of patients with multiple myeloma. Darzalex Uses Approved for the treatment of individuals with multiple myeloma, Darzalex is available as injections, taken intravenously at a 16-mg per kg. Daratumumab may sometimes...
Multiple myeloma is a type of cancer that manifests in a white blood cell known as a plasma cell. Plasma cells play an important role in warding off infections by producing antibodies that identify and strike pathogens. In its early stages, multiple myeloma may not present itself with...
or is an immunotherapy drug that is a more powerful version of drugs such as and . Produced by Celgene, has been approved to be used for the treatment of individuals with myeloma who have previously been on a proteasome inhibitor treatment and also those whose myeloma began advancing...
Chemotherapy is a common treatment method for multiple myeloma that works by introducing cancer-destroying agents into the body. As these chemotherapy drugs enter the bloodstream and circulate throughout the body, they are highly effective in killing myeloma cells. Chemotherapy drugs can either be taken orally or intravenously. If...
If you don’t experience any multiple myeloma symptoms, your oncologist may prefer to monitor your condition closely instead of starting you on a treatment immediately. If you experience symptoms, however, your oncologist will create a treatment protocol based on your particular circumstances. The goal of most multiple myeloma treatments...